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It is well established that the activation of various types ofTlymphocytes requires
recognition by TCRs in association with MHC molecules on the surface ofAPC
or target cells. Class IIMHC molecules regulate the recognition of antigens by Th
cells . It has been suggested that the antigens presented by class II molecules are
preferentially ingested or internalized exogenous proteins (1) andthat theseproteins
are presented in a degraded or a denatured form, rather than in the native form
(2, 3) . Several studies have shown that short peptides, corresponding to mapped an-
tigenic sites of proteins, indeed have thesame stimulatory capacity as the intact pro-
tein (4) . The proteins used for these studies are derived from viruses or bacteria
and, thus, foreign proteins . An interesting question that arises from these findings
is whether peptides derived from selfproteins likeMHC molecules are also presented
to Th cells . Kourilsky et al . (5) have postulated that self, as well as nonself, proteins
can yield peptides presented by theMHC and that alloreactivity could result from
MHC molecules presenting different sets of selfpeptides, including peptides derived
fromMHC molecules themselves . This hypothesis has been supported by the work
of Maryanski et al . (6), who have shown that synthetic peptides derived from class
I molecules can induce class I-specific CTL to lyse mouse cells (6, 7) . It has, how-
ever, never been proven that class II peptides derived from theMHC are presented
to and recognized by Th cells . Here, we show that we have obtained T cell clones
that recognize HLA-DR3 peptides as well as endogenous, denatured HLA-DR3
presented by a molecule from the MHC complex, the HLA-DPw3 molecule .
Materials and Methods
Peptide Synthesis.
￿
The peptide U6 was synthesized in the amide form, using solid phase
peptide synthesis methodology (8-10) and checked using analytical reversed phase HPLC
and amino acid analysis (8) .
The peptide is homologous to the third hypervariable region of the second domain of the
DR3 BI chain (10a) (amino acid 67-85) and has the following amino acid sequence : L L
EQKRGRVDNYCRHNYGV .
T Cell Lines and Clones .
￿
105PBLs were primed in the presence of peptide in a concentra-
tion of 10 hg/ml in RPMI 1640 supplemented with20% pooled human serum andgentamycin
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(50 mg/liter) in V-shaped wells (96-well plates; Cel-Cult, Tissue Culture Products, Felthan,
UK). After 7 d the cultures of -60 wells were collected, spun down, and restimulated with
irradiated autologous feeder cells (3,000 Rad) at a ratio of 10 :1 and peptide in 24-well plates
(Costar, Cambridge, MA). The line was cloned by limiting dilution to 10 or 0.5 cells per
well in the presence ofT cell growth factor (TCGF; Biotest Serum Institut, Frankfurt, FRG)
and autologous irradiated feeder cells. The T cell lines and clones were expanded by serial
exposure to TCGF and peptide as presented by autologousfeedercells. T cell lines and clones
were frozen in small aliquots and stored in liquid nitrogen before use.
Proliferation Studies.
￿
For T cell lines and T cell clones, 20,000 and 5,000 responder cells
per well were used, respectively. The T cell lines or clones were cocultured with 105 irradi-
ated stimulator cells (2,000 Rad) in a total volume of 200 k1 culture medium in flat-bottomed
microtiter plates. After 48 h of incubation (37°C, 5% C02) the cultures were pulsed with
0.05 ml (20 pCi/ml) of tritiated thymidine and harvested 14-16 h later. [3H]Thymidine in-
corporation was then measured by liquid scintillation counting. The indicated cpm represent
the median value of triplicate cultures. The stimulation index (SI) is calculated by dividing
the cpm measured when stimulator and responder are cultured together by the sum of the
cpm measured when stimulator and responder are cultured separately.
nzAbs.
￿
The DR backbone-specific mAb B 8.11.2 (11) was provided by Dr. B. Malissen (the
Ludwig Institute for Cancer Research, Lausanne); the DQantibody SPV.L3 (12) was provided
by Dr. H. Spits (the Netherlands Cancer Institute, Amsterdam); and the mAb A3 (anti-DP)
was obtained from the Tenth International Histocompatibility Workshop, New York (Becton
Dickinson & Co., Mountain View, CA).
Antibody Blocking Assays.
￿
Ascitic fluid was added to the culture in a final dilution of 1 :300
at the initiation of the T cell proliferation assay.
Results and Discussion
PanelReactivity oftheAnti-U6 TCellLine ThoU6.
￿
PBLs from individual Tho (DR4,5;
DQw3 ; DPw3,w4) were in vitro stimulated with a synthetic DR3 peptide (peptide
U6). The obtained T cell line ThoU6 was tested in a proliferation assay for recogni-
tion ofpeptide U6 in the presence ofautologous irradiatedAPC and for recognition
of PBLs of different HLA types. A representative experiment is depicted in Table l.
As expected, ThoU6 recognized peptide U6 presented by autologous APC. In
this experiment two PBL donors also stimulate ThoU6 in the absence of U6. These
PBLs express DR3 and share the expression ofDPw3 with Tho. Therefore, stimula-
tion ofThoU6 might, in these cases, be due to presentation of processed DR3 mole-
TABLE I
Recognition of Peptide U6 and PBLs by T Cell Line ThoU6
The counts represent the median value of triplicate cultures.
Stimulator HLA type
Responder
ThoU6 None
cpm
SdK DR3,3 DQw2 DPw2,w3 78,992 335
Mun DR2,3 DQwl,w2 DPw3,w4 66,779 380
PvtS DR2,3 DQwl,w2 DPw2,w4 805 425
Bier DR2,3 DQwl,w2 DPw2,w4 890 390
Tho DR4,5 DQw3 DPw3,w4 555 425
HeyL DRw6 DQwl DPw3 635 525
JB DR2 DQwl DPw4 415 290
Gul DRw6 DQwl,w3 DPwl,w4 480 110
Tho + peptide U6 (1 jig/ml) 31,470 285
Tho + peptide U6 (10 kg/ml) 86,108 285cules by DPw3. To examine this possibility an extended panel of PBLs was tested
for its stimulatory capacity in the presence and in the absence ofsynthetic peptide.
24 PBLswere tested inthe presence ofpeptideU6 in aconcentrationof10 wg/ml.
11 of 11 DPw3* PBLs, but none ofthe 13 DPw3 - PBLs, were able to stimulate the
line in the presence of peptide.
52 PBLs were tested in the absence of peptide. The results are shown in Fig. 1.
There is a highly significant difference between the stimulation induced by DR3
DPw3* PBLs and PBLs expressing only one or none ofthese antigens (P < 0.0001).
From the results ofthe panel studies, it can be concluded that T cell line ThoU6
recognizes not only syntheticpeptide U6 presented byHLA-DPw3, but also a natu-
rally occurring peptidethat ismostlikely a product ofdenaturation oftheDR3 mol-
ecule. Although we have no formal proofthat the presented antigen is a product
ofDR3, we will refer to it as the natural DR3 peptide. Possibly, the DR3 molecule
is internalized and processed by the APC.
Cloning of ThoU6.
￿
To exclude the possibility that synthetic peptide and dena-
tured DR3 molecules are recognized by two different sets of T cells, ThoU6 was
cloned. Nine clones, five of which originated from 10 cells/well and four from 0.5
cells/well, were tested against a panel of eight PBLs in the presence and absence
ofpeptide U6. The clones all recognized peptide U6 presented by autologous APC
or DPw3* PBLs (n = 2) as well as DR3 DPw3* PBLs (n = 2). None ofthe DR3*
DPw3- (n = 2) or DR3 DPw3 - (n = 2) PBLs were able to stimulate the clones.
As there are no differences in the reactivity patterns ofthe clones, we conclude that
peptide U6 and the natural DR3 peptide are recognized by the same set ofT cells.
Proliferation Inhibition Studies with mAbs.
￿
Because all APC stimulating T cell line
ThoU6 express DPw3, it isvery likely that this molecule presents the DR3 peptide
tothe respondercells. Toprove that theDP molecule is responsible for thepresenta-
tion of antigen, we performed blocking studies with monomorphic mAbs against
DR, DQ, and DP Results ofthe experiment using the original line and two clones
are shown in Fig.2, a-c. When the autologous APC (Tho) and DPw3* DR3- PBLs
(HeyL) were used as stimulators in the presence ofpeptide U6, the anti-DP mono-
clonal could completely block the recognition ofthe peptide. This was also the case
when a DR3 DPw3* stimulator was used in the absence of peptide U6 (Slot).
Therefore, it can be concluded that the DP molecule is indeed responsible for the
presentationofsyntheticpeptide as well as forthepresentation ofnaturalDR3 peptide.
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FIGURE 1.
￿
Reactivity ofT cell line ThoU6 against
a panel of52 PBLs. Specificities DRl to DRw15 and
specificities DPwl to DPw3 are represented. The
panel is divided into DR3* DPw3*, DRY DPw3-,
DR3 - DPw3*, and DR3 - DPw3- stimulators, as
indicated along thex-axis. The stimulation index(SI)
is indicated along the y-axis.1194
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FIGURE2.
￿
Resultsoftheblock-
ing studies with mAbs B8.11.2
(DR), SPV .L3 (DQ), and A3
(DP). Stimulators are autolo-
b T cell clone 2013
￿
gous APC (Tho)in thepresence
stimulator Tho + U6
￿
HeyL + U6
￿
Slot
￿
of U6; DPw3+ DR3" APC
(HeyL) in the presence of U6;
or DR3 DPw3+ PBLs (Slot) in
theabsence ofU6. Responders
are (a) the original T cell line
Th0U6; (b) clone2013; and(c) C T cell clone 201<
clone2014. Resultsof theassays
stimulator
￿
Tho + U6
￿
HeyL + U6
￿
slot
￿
without the addition of mAbs
represent 10070 proliferation.
It has been suggested that allorecognition does not neccessarily have to be recog-
nition ofthe intact HLA molecule, but can be the recognition ofa processed HLA
molecule presented as nominal antigen (5-7, 13, 14). Kourilsky and Claverie (15)
hypothesized that peptides derived from the breakdown of most or all cellular pro-
teins areableto associatewith class I orclassII antigens and wouldthus becontinu-
ously presented atthe surface ofcells. Peptides derived from MHC molecules would
be no exception to this rule (5, 15). So far, there has only been prooffor the class I-
restricted presentationofclass I molecules(6, 7 13). Here, we report ofaDP-restricted
response to DR3 after in vitro sensitization of PBLs with synthetic DR3 peptide.
Ourresults, furthermore, imply a continuous presentation ofnatural DR3 peptides
by DP molecules.
Wehave recently been able to raise a second T cell line that is responsive toboth
synthetic and natural DR3 peptide. This time, the response was restricted through
HLA DRw6 (data not shown). This finding, together with the results discussed in
the present article, suggests that the DR3-derivedpeptidecan probablybe presented
by several HLA class II molecules. The presentation ofnatural, MHC-derived pep-
tides by different self class 11 molecules might have implications for the induction
of self tolerance (16) and, through that, for autoirnmunity and organ transplanta-
tion (17).
Summary
T cell clones raised against a synthetic peptide, identical to the third hypervari-
able region of the DR3 BI chain, were tested for secondary proliferative responses
against a panel ofPBLs. All seven DR3 DPw3+ stimulators could induce prolifer-
ation. DR3- DPw3+ PBLs were recognized when the synthetic peptide was added
tothe cultures. Inhibition studieswith mAbgshowed thatin both casesthe HLA-DP
molecule is involved in the recognition ofboth types of stimulators. We conclude
that the clones recognize the DR3 peptidepresented by HLA-DPw3. This stimulus
can be obtained in two different ways: (a) by addition ofsynthetic peptide to DPw3+
PBLs or (b) by using DR3 DPw3' stimulator cells where DR3 peptides are presentDE KOSTER ET AL.
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in the culture as a product of denaturation of the DR3 molecule. Because all DR3
DPw3+ PBLs tested could stimulate the line and clones, we assume that the pre-
sentation of the DR3 peptide by DP is a naturally and continuously occurring
phenomenon.
We thank Alan Thompson for his generous cooperation.
Receveivedfor publication 10 November 1988.
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